<!doctype html><html><head><title>Active Multiple Myeloma</title><base href="../"><meta id="root-path" root-path="../"><link rel="icon" sizes="96x96" href="https://publish-01.obsidian.md/access/f786db9fac45774fa4f0d8112e232d67/favicon-96x96.png"><meta name="viewport" content="width=device-width,initial-scale=1,user-scalable=yes,minimum-scale=1,maximum-scale=5"><meta charset="UTF-8"><link rel="stylesheet" href="lib/styles/obsidian-styles.css"><link rel="stylesheet" href="lib/styles/theme.css"><link rel="stylesheet" href="lib/styles/plugin-styles.css"><link rel="stylesheet" href="lib/styles/snippets.css"><link rel="stylesheet" href="lib/styles/generated-styles.css"><style></style><script type="module" src="lib/scripts/graph_view.js"></script><script src="lib/scripts/graph_wasm.js"></script><script src="lib/scripts/tinycolor.js"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/pixi.js/7.2.4/pixi.min.js" integrity="sha512-Ch/O6kL8BqUwAfCF7Ie5SX1Hin+BJgYH4pNjRqXdTEqMsis1TUYg+j6nnI9uduPjGaj7DN4UKCZgpvoExt6dkw==" crossorigin="anonymous" referrerpolicy="no-referrer"></script><script src="lib/scripts/webpage.js"></script><script src="lib/scripts/generated.js"></script></head><body class="theme-light show-inline-title loading"><div class="webpage-container"><div class="sidebar-left sidebar"><div class="sidebar-container"><div class="sidebar-sizer"><div class="sidebar-content-positioner"><div class="sidebar-content"><div><label class="theme-toggle-container" for="theme_toggle"><input class="theme-toggle-input" type="checkbox" id="theme_toggle"><div class="toggle-background"></div></label></div><div class="tree-container file-tree mod-nav-indicator" data-depth="0"><div class="tree-header"><span class="sidebar-section-header">Notes</span><button class="clickable-icon collapse-tree-button is-collapsed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"></svg></button></div><div class="tree-scroll-area"><div class="tree-item mod-tree-folder mod-collapsible is-collapsed" data-depth="1"><div class="tree-item-contents"><a class="internal-link tree-item-link"><div class="tree-item-icon collapse-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon right-triangle"><path d="M3 8L12 17L21 8"></path></svg></div><span class="tree-item-title">Plasma Cell Disorders</span></a></div><div class="tree-item-children" style="display:none"><div class="tree-item mod-tree-file" data-depth="2"><div class="tree-item-contents"><a class="internal-link tree-item-link" href="plasma-cell-disorders/active-multiple-myeloma.html"><span class="tree-item-title">Active Multiple Myeloma</span></a></div><div class="tree-item-children"></div></div><div class="tree-item mod-tree-file" data-depth="2"><div class="tree-item-contents"><a class="internal-link tree-item-link" href="plasma-cell-disorders/al-amyloidosis.html"><span class="tree-item-title">AL Amyloidosis</span></a></div><div class="tree-item-children"></div></div><div class="tree-item mod-tree-file" data-depth="2"><div class="tree-item-contents"><a class="internal-link tree-item-link" href="plasma-cell-disorders/amyloidosis-nejm.html"><span class="tree-item-title">Amyloidosis NEJM</span></a></div><div class="tree-item-children"></div></div><div class="tree-item mod-tree-file" data-depth="2"><div class="tree-item-contents"><a class="internal-link tree-item-link" href="plasma-cell-disorders/amyloidosis_-general.html"><span class="tree-item-title">Amyloidosis_ general</span></a></div><div class="tree-item-children"></div></div><div class="tree-item mod-tree-file" data-depth="2"><div class="tree-item-contents"><a class="internal-link tree-item-link" href="plasma-cell-disorders/mgus-monoclonal-gammopathy-of-undetermined-signi.html"><span class="tree-item-title">MGUS - Monoclonal Gammopathy of Undetermined Signi</span></a></div><div class="tree-item-children"></div></div><div class="tree-item mod-tree-file" data-depth="2"><div class="tree-item-contents"><a class="internal-link tree-item-link" href="plasma-cell-disorders/monoclonal-gammopathy-disorders-(fellow).html"><span class="tree-item-title">Monoclonal Gammopathy Disorders (Fellow)</span></a></div><div class="tree-item-children"></div></div></div></div></div></div></div></div></div></div><div class="sidebar-gutter"><div class="clickable-icon sidebar-collapse-icon"><svg xmlns="http://www.w3.org/2000/svg" width="100%" height="100%" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="3" stroke-linecap="round" stroke-linejoin="round" class="svg-icon"><path d="M21 3H3C1.89543 3 1 3.89543 1 5V19C1 20.1046 1.89543 21 3 21H21C22.1046 21 23 20.1046 23 19V5C23 3.89543 22.1046 3 21 3Z"></path><path d="M10 4V20"></path><path d="M4 7H7"></path><path d="M4 10H7"></path><path d="M4 13H7"></path></svg></div></div></div><div class="document-container show"><div class="markdown-preview-view markdown-rendered node-insert-event allow-fold-headings show-indentation-guide allow-fold-lists show-properties" style="tab-size:4"><style id="MJX-CHTML-styles">mjx-container[jax=CHTML]{line-height:0}mjx-container [space="1"]{margin-left:.111em}mjx-container [space="2"]{margin-left:.167em}mjx-container [space="3"]{margin-left:.222em}mjx-container [space="4"]{margin-left:.278em}mjx-container [space="5"]{margin-left:.333em}mjx-container [rspace="1"]{margin-right:.111em}mjx-container [rspace="2"]{margin-right:.167em}mjx-container [rspace="3"]{margin-right:.222em}mjx-container [rspace="4"]{margin-right:.278em}mjx-container [rspace="5"]{margin-right:.333em}mjx-container [size="s"]{font-size:70.7%}mjx-container [size=ss]{font-size:50%}mjx-container [size=Tn]{font-size:60%}mjx-container [size=sm]{font-size:85%}mjx-container [size=lg]{font-size:120%}mjx-container [size=Lg]{font-size:144%}mjx-container [size=LG]{font-size:173%}mjx-container [size=hg]{font-size:207%}mjx-container [size=HG]{font-size:249%}mjx-container [width=full]{width:100%}mjx-box{display:inline-block}mjx-block{display:block}mjx-itable{display:inline-table}mjx-row{display:table-row}mjx-row>*{display:table-cell}mjx-mtext{display:inline-block;text-align:left}mjx-mstyle{display:inline-block}mjx-merror{display:inline-block;color:red;background-color:#ff0}mjx-mphantom{visibility:hidden}mjx-assistive-mml{top:0;left:0;clip:rect(1px,1px,1px,1px);user-select:none;position:absolute!important;padding:1px 0 0!important;border:0!important;display:block!important;width:auto!important;overflow:hidden!important}mjx-assistive-mml[display=block]{width:100%!important}mjx-math{display:inline-block;text-align:left;line-height:0;text-indent:0;font-style:normal;font-weight:400;font-size:100%;letter-spacing:normal;border-collapse:collapse;overflow-wrap:normal;word-spacing:normal;white-space:nowrap;direction:ltr;padding:1px 0}mjx-container[jax=CHTML][display=true]{display:block;text-align:center;margin:1em 0}mjx-container[jax=CHTML][display=true][width=full]{display:flex}mjx-container[jax=CHTML][display=true] mjx-math{padding:0}mjx-container[jax=CHTML][justify=left]{text-align:left}mjx-container[jax=CHTML][justify=right]{text-align:right}mjx-c{display:inline-block}mjx-utext{display:inline-block;padding:.75em 0 .2em}mjx-mi{display:inline-block;text-align:left}mjx-msub{display:inline-block;text-align:left}mjx-mn{display:inline-block;text-align:left}mjx-mo{display:inline-block;text-align:left}mjx-stretchy-h{display:inline-table;width:100%}mjx-stretchy-h>*{display:table-cell;width:0}mjx-stretchy-h>*>mjx-c{display:inline-block;transform:scaleX(1)}mjx-stretchy-h>*>mjx-c::before{display:inline-block;width:initial}mjx-stretchy-h>mjx-ext{overflow:clip visible;width:100%}mjx-stretchy-h>mjx-ext>mjx-c::before{transform:scaleX(500)}mjx-stretchy-h>mjx-ext>mjx-c{width:0}mjx-stretchy-h>mjx-beg>mjx-c{margin-right:-.1em}mjx-stretchy-h>mjx-end>mjx-c{margin-left:-.1em}mjx-stretchy-v{display:inline-block}mjx-stretchy-v>*{display:block}mjx-stretchy-v>mjx-beg{height:0}mjx-stretchy-v>mjx-end>mjx-c{display:block}mjx-stretchy-v>*>mjx-c{transform:scaleY(1);transform-origin:left center;overflow:hidden}mjx-stretchy-v>mjx-ext{display:block;height:100%;box-sizing:border-box;border:0 solid transparent;overflow:visible clip}mjx-stretchy-v>mjx-ext>mjx-c::before{width:initial;box-sizing:border-box}mjx-stretchy-v>mjx-ext>mjx-c{transform:scaleY(500) translateY(.075em);overflow:visible}mjx-mark{display:inline-block;height:0}mjx-c::before{display:block;width:0}.MJX-TEX{font-family:MJXZERO,MJXTEX}.TEX-B{font-family:MJXZERO,MJXTEX-B}.TEX-I{font-family:MJXZERO,MJXTEX-I}.TEX-MI{font-family:MJXZERO,MJXTEX-MI}.TEX-BI{font-family:MJXZERO,MJXTEX-BI}.TEX-S1{font-family:MJXZERO,MJXTEX-S1}.TEX-S2{font-family:MJXZERO,MJXTEX-S2}.TEX-S3{font-family:MJXZERO,MJXTEX-S3}.TEX-S4{font-family:MJXZERO,MJXTEX-S4}.TEX-A{font-family:MJXZERO,MJXTEX-A}.TEX-C{font-family:MJXZERO,MJXTEX-C}.TEX-CB{font-family:MJXZERO,MJXTEX-CB}.TEX-FR{font-family:MJXZERO,MJXTEX-FR}.TEX-FRB{font-family:MJXZERO,MJXTEX-FRB}.TEX-SS{font-family:MJXZERO,MJXTEX-SS}.TEX-SSB{font-family:MJXZERO,MJXTEX-SSB}.TEX-SSI{font-family:MJXZERO,MJXTEX-SSI}.TEX-SC{font-family:MJXZERO,MJXTEX-SC}.TEX-T{font-family:MJXZERO,MJXTEX-T}.TEX-V{font-family:MJXZERO,MJXTEX-V}.TEX-VB{font-family:MJXZERO,MJXTEX-VB}mjx-stretchy-h mjx-c,mjx-stretchy-v mjx-c{font-family:MJXZERO,MJXTEX-S1,MJXTEX-S4,MJXTEX,MJXTEX-A!important}@font-face{font-family:MJXZERO;src:url("https://publish.obsidian.md/lib/mathjax/output/chtml/fonts/woff-v2/MathJax_Zero.woff") format("woff")}@font-face{font-family:MJXTEX;src:url("https://publish.obsidian.md/lib/mathjax/output/chtml/fonts/woff-v2/MathJax_Main-Regular.woff") format("woff")}@font-face{font-family:MJXTEX-B;src:url("https://publish.obsidian.md/lib/mathjax/output/chtml/fonts/woff-v2/MathJax_Main-Bold.woff") format("woff")}@font-face{font-family:MJXTEX-I;src:url("https://publish.obsidian.md/lib/mathjax/output/chtml/fonts/woff-v2/MathJax_Math-Italic.woff") format("woff")}@font-face{font-family:MJXTEX-MI;src:url("https://publish.obsidian.md/lib/mathjax/output/chtml/fonts/woff-v2/MathJax_Main-Italic.woff") format("woff")}@font-face{font-family:MJXTEX-BI;src:url("https://publish.obsidian.md/lib/mathjax/output/chtml/fonts/woff-v2/MathJax_Math-BoldItalic.woff") format("woff")}@font-face{font-family:MJXTEX-S1;src:url("https://publish.obsidian.md/lib/mathjax/output/chtml/fonts/woff-v2/MathJax_Size1-Regular.woff") format("woff")}@font-face{font-family:MJXTEX-S2;src:url("https://publish.obsidian.md/lib/mathjax/output/chtml/fonts/woff-v2/MathJax_Size2-Regular.woff") format("woff")}@font-face{font-family:MJXTEX-S3;src:url("https://publish.obsidian.md/lib/mathjax/output/chtml/fonts/woff-v2/MathJax_Size3-Regular.woff") format("woff")}@font-face{font-family:MJXTEX-S4;src:url("https://publish.obsidian.md/lib/mathjax/output/chtml/fonts/woff-v2/MathJax_Size4-Regular.woff") format("woff")}@font-face{font-family:MJXTEX-A;src:url("https://publish.obsidian.md/lib/mathjax/output/chtml/fonts/woff-v2/MathJax_AMS-Regular.woff") format("woff")}@font-face{font-family:MJXTEX-C;src:url("https://publish.obsidian.md/lib/mathjax/output/chtml/fonts/woff-v2/MathJax_Calligraphic-Regular.woff") format("woff")}@font-face{font-family:MJXTEX-CB;src:url("https://publish.obsidian.md/lib/mathjax/output/chtml/fonts/woff-v2/MathJax_Calligraphic-Bold.woff") format("woff")}@font-face{font-family:MJXTEX-FR;src:url("https://publish.obsidian.md/lib/mathjax/output/chtml/fonts/woff-v2/MathJax_Fraktur-Regular.woff") format("woff")}@font-face{font-family:MJXTEX-FRB;src:url("https://publish.obsidian.md/lib/mathjax/output/chtml/fonts/woff-v2/MathJax_Fraktur-Bold.woff") format("woff")}@font-face{font-family:MJXTEX-SS;src:url("https://publish.obsidian.md/lib/mathjax/output/chtml/fonts/woff-v2/MathJax_SansSerif-Regular.woff") format("woff")}@font-face{font-family:MJXTEX-SSB;src:url("https://publish.obsidian.md/lib/mathjax/output/chtml/fonts/woff-v2/MathJax_SansSerif-Bold.woff") format("woff")}@font-face{font-family:MJXTEX-SSI;src:url("https://publish.obsidian.md/lib/mathjax/output/chtml/fonts/woff-v2/MathJax_SansSerif-Italic.woff") format("woff")}@font-face{font-family:MJXTEX-SC;src:url("https://publish.obsidian.md/lib/mathjax/output/chtml/fonts/woff-v2/MathJax_Script-Regular.woff") format("woff")}@font-face{font-family:MJXTEX-T;src:url("https://publish.obsidian.md/lib/mathjax/output/chtml/fonts/woff-v2/MathJax_Typewriter-Regular.woff") format("woff")}@font-face{font-family:MJXTEX-V;src:url("https://publish.obsidian.md/lib/mathjax/output/chtml/fonts/woff-v2/MathJax_Vector-Regular.woff") format("woff")}@font-face{font-family:MJXTEX-VB;src:url("https://publish.obsidian.md/lib/mathjax/output/chtml/fonts/woff-v2/MathJax_Vector-Bold.woff") format("woff")}mjx-c.mjx-c31::before{padding:.666em .5em 0 0;content:"1"}mjx-c.mjx-c1D45F.TEX-I::before{padding:.442em .451em .011em 0;content:"r"}mjx-c.mjx-c5C::before{padding:.75em .5em .25em 0;content:"\\"}mjx-c.mjx-c51::before{padding:.705em .778em .193em 0;content:"Q"}mjx-c.mjx-c1D45D.TEX-I::before{padding:.442em .503em .194em 0;content:"p"}mjx-c.mjx-c3D::before{padding:.583em .778em .082em 0;content:"="}mjx-c.mjx-c1D43A.TEX-I::before{padding:.705em .786em .022em 0;content:"G"}mjx-c.mjx-c1D438.TEX-I::before{padding:.68em .764em 0 0;content:"E"}mjx-c.mjx-c29::before{padding:.75em .389em .25em 0;content:")"}mjx-c.mjx-cA0::before{padding:0 .25em 0 0;content:" "}mjx-c.mjx-c1D454.TEX-I::before{padding:.442em .477em .205em 0;content:"g"}mjx-c.mjx-c1D439.TEX-I::before{padding:.68em .749em 0 0;content:"F"}mjx-c.mjx-c1D43C.TEX-I::before{padding:.683em .504em 0 0;content:"I"}mjx-c.mjx-c1D43D.TEX-I::before{padding:.683em .633em .022em 0;content:"J"}</style><div class="markdown-preview-sizer markdown-preview-section" style="min-height:26997px"><div class="markdown-preview-pusher" style="width:1px;height:.1px;margin-bottom:0"></div><div class="mod-header"></div><div><hr></div><div><p>title: Active Multiple Myeloma<br>updated: 2022-01-25 16:09:54Z<br>created: 2021-07-12 23:16:33Z</p></div><div><hr></div><div><p><strong>Definition&nbsp;</strong></p></div><div><ul><li data-line="0">Neoplastic, clonal proliferation of plasma cells producing monoclonal immunoglobulin (usually M protein) resulting in endprognos-organ dysfunction</li><li data-line="1">Usually mono-clonal and secretory</li></ul></div><div><p></p><div width="425" alt="image.png" src="lib\media\image-623.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-623.png" style="width:425px;max-width:100%"></div><p></p></div><div><p><strong>Epidemiology</strong><br>**<br>**</p></div><div><ul><li data-line="0">Affects older people, median age 68y, M &gt; F, blacks &gt; whites</li><li data-line="1">2% of all cancers in US</li><li data-line="2">Half survive at 5 years</li></ul></div><div><p></p><div width="475" alt="image.png" src="lib\media\image-616.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-616.png" style="width:475px;max-width:100%"></div><p></p></div><div><p><strong>Variant</strong></p></div><div><p><strong>Non-secretory Myeloma</strong></p></div><div><p>Esp. IgD and IgE<br></p><div width="425" alt="image.png" src="lib\media\image-617.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-617.png" style="width:425px;max-width:100%"></div><p></p></div><div><p><strong>Plasma Cell Leukemia</strong></p></div><div><p></p><div alt="image.png" src="lib\media\image-615.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-615.png"></div><p></p></div><div><p><strong>Pathophysiology</strong><br>**<br>**<br></p><div alt="image.png" src="lib\media\image-(1686297422364).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297422364).png"></div><p></p></div><div><ul><li data-line="0"><p>Malignant plasma cell line secretes monoclonal antibody</p></li><li data-line="1"><p><strong>95% produce M protein (</strong>monoclogal Ig = identical heavy chain + identical light chain; OR light chain only)</p><ul><li data-line="2"><p>IgG 50%, IgA 20%, IgD 2%, IgM 0.5%)</p></li><li data-line="3"><p>15-20% produce free <strong>light chains only</strong></p></li><li data-line="4"><p>&lt;5% secrete nothing</p><ul><li data-line="5"><p>Oligosecretory</p></li><li data-line="6"><p></p><div alt="image.png" src="lib\media\image-(1686297425287).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297425287).png"></div><p></p></li><li data-line="8"></li></ul></li></ul></li><li data-line="10"><p><strong>Light chains</strong></p><ul><li data-line="11">Found in Serum as Kappa or Lambda light chain. Kappa &gt; lamda has better prognosis</li><li data-line="12">Found in Urine as Bence-Jones protein</li></ul></li></ul></div><div><p><strong>CKD and K/L</strong></p></div><div><ul><li data-line="0">The rapid turnover of FLC (2-6 hours) as compared with IgG (23 days) and other immunoglobulins (ie, Ig: 5.8 days; IgM: 5.1 days; IgD: 2.8 days; IgE: 2.3 days) contribute to FLC lability and thus make it a useful disease burden monitoring tool</li><li data-line="1">Normally, K / L production ratio is 2:1.&nbsp; K/L ratio is &lt; 1 because kappa is a monomer and cleared more readily by kidneys. Under CKD, K/L ratio is &gt;1 because kappa chains cannot be cleared, and both are cleared by the reticuloendothelial system</li></ul></div><div><p><strong>Cytogenetics</strong><br>**<br>**<br></p><div width="525" alt="image.png" src="lib\media\image-388.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-388.png" style="width:525px;max-width:100%"></div><p></p></div><div><p></p><div alt="image.png" src="lib\media\image-390.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-390.png"></div><div alt="image.png" src="lib\media\image-377.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-377.png"></div><p></p></div><div><p>Molecular characteristics matter, same translocation can be standard or high risk!</p></div><div><p></p><div alt="image.png" src="lib\media\image-385.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-385.png"></div><br>Can relapse with <strong>different </strong>cyogenetics<p></p></div><div><p></p><div alt="image.png" src="lib\media\image-387.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-387.png"></div><p></p></div><div><p></p><div alt="image.png" src="lib\media\image-391.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-391.png"></div><div alt="image.png" src="lib\media\image-374.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-374.png"></div><div alt="image.png" src="lib\media\image-386.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-386.png"></div><p></p></div><div><p>6% are '<strong>double hit</strong>', with 1q amplification and tp53 mutations</p></div><div><p>MRD After Diagnosis<br></p><div alt="image.png" src="lib\media\image-389.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-389.png"></div><p></p></div><div><p><strong>Diagnosis</strong><br>**<br>**<br></p><div width="500" alt="image.png" src="lib\media\image-(1686297421673).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297421673).png" style="width:500px;max-width:100%"></div><p></p></div><div class="heading-wrapper"><h3 data-heading="**Clinical Features and Complications (SLIM CRAB HANd)**" class="heading" id="**Clinical_Features_and_Complications_(SLIM_CRAB_HANd)**"><div class="heading-before"></div><div class="heading-collapse-indicator collapse-indicator collapse-icon"><svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon right-triangle" style="width:24px;max-width:100%"><path d="M3 8L12 17L21 8"></path></svg></div><strong>Clinical Features and Complications (SLIM CRAB HANd)</strong><div class="heading-after">...</div></h3><div class="heading-children"><div><p>*<em><br>**<br></em>amyloidosis, if actually attributable to myeloma, makes you myeloma too!<br>**<br>**</p></div><div><ul><li data-line="0"><p><strong>S</strong> stands for 60%: those patients who have 60% or more clonal plasma cells in the bone marrow were so likely to progress that they ought to be treated and are now classified as symptomatic myeloma</p></li><li data-line="2"><p><strong>Li</strong> stands for light chains: those patients with a kappa-to-lambda or lambda-to-kappa ratio of greater than 100 are so likely to progress to needing treatment that they should be treated at the time of diagnosis</p></li><li data-line="4"><p><strong>M</strong> stands for MRI: patients with more than one focal lesion on MRI now have transitioned from smoldering myeloma to symptomatic disease warranting therapy</p></li><li data-line="5"><p><strong>HyperCalcemia</strong></p><ul><li data-line="6">Bones, groans, moans, stones, psychiatric overtones</li><li data-line="7">Polyuria, polydipsia</li></ul></li><li data-line="8"><p><strong>Renal disease</strong></p><ul><li data-line="9">Cast nephropathy, particularly from light chain disease</li><li data-line="10">BUN to Cr ratio of &lt;20:1 (intinsic injury to kidney)</li><li data-line="11">Immediate treatment: proteasome inhibitor salvages the kidney</li><li data-line="12">Urine sediment should be bland (nephrotic range proteinuria with MGS is uncommon; you need to have a renal biopsy at that point)</li></ul></li><li data-line="13"><p><strong>Anemia</strong></p><ul><li data-line="14">Normocytic anemia</li><li data-line="15">Weakness, fatigue, pallor</li><li data-line="16">From bone marrow suppression</li><li data-line="17">Rouleaux formation</li></ul></li><li data-line="18"><p><strong>Bone Disease (70%)</strong></p><ul><li data-line="19">Pain (back)</li><li data-line="20">Pathological fractures</li><li data-line="21">Lytic lesions (skull, spine, ribs, proximal long bones)</li><li data-line="22">Increased bone resorption secondary to PTHrP</li><li data-line="23">Due to osteoclast activating factor</li><li data-line="24">MIRELS Score</li></ul></li><li data-line="25"><p>Weight loss</p></li><li data-line="26"><p>Infections</p><ul><li data-line="27">S. Pneumo and Gram -, secondary to plasma cell dysfunction</li></ul></li><li data-line="28"><p>Bleeding</p><ul><li data-line="29">thrombocytopenia</li><li data-line="30">acquired vWD</li></ul></li><li data-line="31"><p>Extra-medullary plasmacytoma</p><ul><li data-line="32">Soft tissue mass composed o fmonoclonal plasma cells</li></ul></li><li data-line="33"><p><strong>Hyperviscosity&nbsp;</strong></p><ul><li data-line="34"><p>Strokes, headache, angina, MI</p></li><li data-line="35"><p>M protein hyperviscosity</p></li><li data-line="36"><p></p><div alt="image.png" src="lib\media\image-653.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-653.png"></div><p></p></li><li data-line="38"></li></ul></li></ul></div></div></div><div class="heading-wrapper"><h3 data-heading="**Amyloidosis**" class="heading" id="**Amyloidosis**"><div class="heading-before"></div><div class="heading-collapse-indicator collapse-indicator collapse-icon"><svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon right-triangle" style="width:24px;max-width:100%"><path d="M3 8L12 17L21 8"></path></svg></div><strong>Amyloidosis</strong><div class="heading-after">...</div></h3><div class="heading-children"><div><pre><code>- Accumulation of insoluble fibrillar protein (Ig light chain in tissues)
- Cardiac (HFpEF, arrythmias, syncope)
- GI (malabsorption, large tongue)
- Neurologic (orthostatic hypotension, carpal tunnel)
- Factor 10 deficiency (racoon eyes)
</code><button class="copy-code-button">Copy</button></pre></div><div><ul><li data-line="0"><strong>Neurological</strong><ul><li data-line="1">Muscle weakness, pain, parathesia</li><li data-line="2">Spinal cord compression</li><li data-line="3"><em>Nerve entrapment from bone collapse&nbsp;</em></li></ul></li></ul></div></div></div><div class="heading-wrapper"><h3 data-heading="**Revised Staging System for Myeloma (RISS) **" class="heading" id="**Revised_Staging_System_for_Myeloma_(RISS)_**"><div class="heading-before"></div><div class="heading-collapse-indicator collapse-indicator collapse-icon"><svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon right-triangle" style="width:24px;max-width:100%"><path d="M3 8L12 17L21 8"></path></svg></div><strong>Revised Staging System for Myeloma (RISS)</strong><div class="heading-after">...</div></h3><div class="heading-children"><div><p></p><div alt="image.png" src="lib\media\image-620.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-620.png"></div><p></p></div><div><p><strong>Risk Stratification</strong></p></div><div><p>The <strong>Medical Research Council IX </strong>trial identified 3 groups:89</p></div><div><ol><li data-line="0"><p><strong>Favorable risk</strong> [no adverse IgH translocation, del(17p), or gain(1q)]</p></li><li data-line="1"><p><strong>Intermediate risk</strong> (1 adverse chromosomal abnormality),</p></li><li data-line="2"><p><strong>High-risk</strong> (&gt; 1 adverse chromosomal abnormality).</p></li><li data-line="4"><p><strong>Ultra-high-risk </strong>was defined as &gt;2 chromosomal aberrations (2% of patients).</p></li></ol></div><div><p>Median progression-free survival (PFS) and OS of patients in the favorable-, intermediate-, and high-risk groups were 23.5, 17.8, and 11.7 months and 60.6, 41.9, and 21.7 months, respectively. Median OS in the ultra-high-risk group was 9 months.</p></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297228314).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297228314).png"></div><p></p></div><div><p>Memorize the high risk mutations 4;14, 14;16, 17p</p></div><div><p></p><div width="400" alt="image.png" src="lib\media\image-(1686297422163).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297422163).png" style="width:400px;max-width:100%"></div><p></p></div><div><p><strong>Diagnosis</strong><br>**<br>**</p></div><div><ul><li data-line="0">SLIMCRAB + End organ damage (including AL amyloidosis)</li></ul></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297423832).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297423832).png"></div><p></p></div><div><ul><li data-line="0">See main article for investigations</li></ul></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297422690).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297422690).png"></div><p></p></div><div><p><strong>Bone Marrow</strong><br></p><div alt="image.png" src="lib\media\image-(1686297426529).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297426529).png"></div><p></p></div><div><p><strong>Staging</strong><br></p><div alt="image.png" src="lib\media\image-(1686297425743).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297425743).png"></div><p></p></div></div></div><div class="heading-wrapper"><h1 data-heading="Management" class="heading" id="Management"><div class="heading-before"></div>Management<div class="heading-after">...</div></h1><div class="heading-children"><div><p></p><div width="450" alt="image.png" src="lib\media\image-614.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-614.png" style="width:450px;max-width:100%"></div><p></p></div><div class="heading-wrapper"><h3 data-heading="**Management: Initial**" class="heading" id="**Management:_Initial**"><div class="heading-before"></div><div class="heading-collapse-indicator collapse-indicator collapse-icon"><svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon right-triangle" style="width:24px;max-width:100%"><path d="M3 8L12 17L21 8"></path></svg></div><strong>Management: Initial</strong><div class="heading-after">...</div></h3><div class="heading-children"><div><p>Agents: <a data-tooltip-position="top" aria-label="evernote:///view/16130042/s156/b7a63fa7-1015-c611-c2c6-09bf0dcd5811/22832c1a-34ab-449f-a394-cc556850e328/" rel="noopener" class="external-link" href="evernote:///view/16130042/s156/b7a63fa7-1015-c611-c2c6-09bf0dcd5811/22832c1a-34ab-449f-a394-cc556850e328/" target="_blank">Anti-Myeloma Agents</a></p></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297423186).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297423186).png"></div><p></p></div><div><p></p><div width="500" alt="image.png" src="lib\media\image-(1686297421336).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297421336).png" style="width:500px;max-width:100%"></div><p></p></div><div><p></p><div width="400" alt="image.png" src="lib\media\image-(1686297426299).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297426299).png" style="width:400px;max-width:100%"></div><p></p></div></div></div><div class="heading-wrapper"><h2 data-heading="**General Principles**" class="heading" id="**General_Principles**"><div class="heading-before"></div><div class="heading-collapse-indicator collapse-indicator collapse-icon"><svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon right-triangle" style="width:24px;max-width:100%"><path d="M3 8L12 17L21 8"></path></svg></div><strong>General Principles</strong><div class="heading-after">...</div></h2><div class="heading-children"><div><ul><li data-line="0"><p>Non-curative</p></li><li data-line="2"><p>Goals: improve QOL, prevent progression, 3-drug combinations</p></li><li data-line="4"><p>Transplant Eligibility</p><ul><li data-line="5"><div width="500" alt="image.png" src="lib\media\image-(1686297424203).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297424203).png" style="width:500px;max-width:100%"></div></li></ul></li></ul></div><div><p><strong>Big fork: transplant eligible or not</strong><br></p><div width="500" alt="image.png" src="lib\media\image-(1686297420951).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297420951).png" style="width:500px;max-width:100%"></div><p></p></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297423022).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297423022).png"></div><p></p></div><div><p></p><div width="500" alt="image.png" src="lib\media\image-(1686297426111).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297426111).png" style="width:500px;max-width:100%"></div><p></p></div><div><p></p><div width="500" alt="image.png" src="lib\media\image-(1686297421933).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297421933).png" style="width:500px;max-width:100%"></div><p></p></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297424399).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297424399).png"></div><p></p></div><div><p><strong>Transplant Ineligible:</strong></p></div><div><p></p><div width="500" alt="image.png" src="lib\media\image-(1686297421499).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297421499).png" style="width:500px;max-width:100%"></div><br>Chemotherapy &gt;65 y<p></p></div><div><ul><li data-line="0">3 drug combination as initial therapy --&gt; better OS</li><li data-line="1">lenalidomide, prednisone, bortezomib</li></ul></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297422860).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297422860).png"></div><p></p></div><div><ul><li data-line="0"><p>len/dex/melphalan<br>-</p><div alt="image.png" src="lib\media\image-(1686297425934).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297425934).png"></div><p></p><pre><code>  -
</code><button class="copy-code-button">Copy</button></pre></li><li data-line="5"><p>len/daratumumab/dex<br>-</p><div alt="image.png" src="lib\media\image-(1686297423370).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297423370).png"></div><p></p></li></ul></div><div><p><strong>Transplant Eligible:</strong><br>**<br>**<br></p><div width="500" alt="image.png" src="lib\media\image-(1686297422525).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297422525).png" style="width:500px;max-width:100%"></div><p></p></div><div><p>Autologous SCT &lt;70?</p></div><div><ul><li data-line="0"><p>High dose chemo induction&nbsp; + Conditioning/Auto-SCT + Maintenance therapy</p><ul><li data-line="1"><p>Induction regimen</p><ul><li data-line="2"><p></p><div width="500" alt="image.png" src="lib\media\image-(1686297424017).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297424017).png" style="width:500px;max-width:100%"></div><p></p></li><li data-line="4"></li></ul></li><li data-line="6"><p>Mixed data for tandem transplant</p></li><li data-line="7"></li><li data-line="8"><p>Lenalidomide Maintenance therapy does improve survival</p><ul><li data-line="9"><p></p><div alt="image.png" src="lib\media\image-618.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-618.png"></div><p></p></li><li data-line="10"><p></p><div width="500" alt="image.png" src="lib\media\image-(1686297424922).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297424922).png" style="width:500px;max-width:100%"></div><p></p></li><li data-line="12"></li></ul></li></ul></li><li data-line="14"><p>Usually 4-6 months of cytoreductive therapy with novel agents (linedomide or proteasome inhibitor)</p><ul><li data-line="15"><p></p><div alt="6b2dacb57ccef288bec26372cfc90706" src="../_resources/6b2dacb57ccef288bec26372cfc90706" class="internal-embed is-loaded file-embed mod-empty-attachment">“../_resources/6b2dacb57ccef288bec26372cfc90706” could not be found.</div><p></p></li><li data-line="17"><p></p><div width="500" alt="image.png" src="lib\media\image-(1686297425516).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297425516).png" style="width:500px;max-width:100%"></div><p></p></li></ul></li></ul></div><div><p>Dara does not seem to work well in high risk patients</p></div><div><p><strong>Tandem Transplant data</strong><br></p><div width="700" alt="image.png" src="lib\media\image-(1686297423615).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297423615).png" style="width:700px;max-width:100%"></div><p></p></div><div><p><strong>High Risk Cytogenetics Options</strong><br>**<br>**<br></p><div width="980" alt="image.png" src="lib\media\image-624.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-624.png" style="width:980px;max-width:100%"></div><br>All treatments work less well<p></p></div><div><ul><li data-line="0"><p>Dara-VTD-ASCT</p></li><li data-line="1"><p>KRd-ASCT</p></li><li data-line="2"><p>Tandem transplant: PFS benefit</p></li><li data-line="3"><p>Maintenance: two-agent maintenance, eg DR or VR</p><ul><li data-line="4"><p></p><div width="500" alt="image.png" src="lib\media\image-622.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-622.png" style="width:500px;max-width:100%"></div><p></p></li><li data-line="6"></li></ul></li></ul></div><div><p>Ultra-high risk NDMM:</p></div><div><p></p><div alt="image.png" src="lib\media\image-621.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-621.png"></div><p></p></div><div><p>Phase 2 GMMG Concept Study: Isa KRD<br></p><div alt="image.png" src="lib\media\image-(1686297421170).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297421170).png"></div><p></p></div><div><p>Phase 2 Master Study: Dara-KRD / ASCT / more consolidation<br></p><div alt="image.png" src="lib\media\image-(1686297425103).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297425103).png"></div><p></p></div><div><p><strong>Monitoring Response</strong></p></div><div><p></p><div alt="image.png" src="lib\media\image-619.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-619.png"></div><p></p></div><div><p></p><div alt="image.png" src="lib\media\image-(1686297426756).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297426756).png"></div><p></p></div><div><p>Used to track MRD for Plasma cells (all are aberrant markers)<br></p><div width="500" alt="image.png" src="lib\media\image-(1686297424700).png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-(1686297424700).png" style="width:500px;max-width:100%"></div><p></p></div><div><p><strong>Supportive</strong></p></div><div><ul><li data-line="0"><p>Bone Disease</p><ul><li data-line="1">Bisphosphonates for osteopenia or lytic bone lesions (renal dosed)<ul><li data-line="2">Pamidronate or Zoledronic Acid -&gt; zoledronic acid improves survival</li><li data-line="3">Denosumab</li><li data-line="4">Risk of osteonecrosis of the Jaw</li></ul></li><li data-line="5">Kyphoplasty/Vertebroplasty for vertebral fractuers</li><li data-line="6">Local XRT for bone pain</li></ul></li><li data-line="8"><p>Treat Hypercalcemia</p></li><li data-line="9"><p>Treat hypogammaglobulinemia</p></li><li data-line="10"><p>Prophylactic Abx</p><ul><li data-line="11">PJP on high dose steroids</li><li data-line="12">VZV on proteasome inhibitors</li><li data-line="13">Levofloxacin for at least 3 months</li></ul></li><li data-line="14"><p>EPO for anemia</p></li><li data-line="15"><p>DVT prophylaxis</p><ul><li data-line="16">No risk factors: ASA 81 mg</li><li data-line="17"><blockquote><p>2 risk factors = LMWH</p></blockquote></li><li data-line="18">LMWH if &gt; 2 risk factors</li><li data-line="19">Especially high for lenalidomide treated</li><li data-line="20"><div alt="image.png" src="lib\media\image-626.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-626.png"></div></li><li data-line="21">Risk factors</li><li data-line="22"><div alt="image.png" src="lib\media\image-625.png" class="internal-embed media-embed image-embed is-loaded"><img alt="image.png" src="lib\media\image-625.png"></div></li></ul></li></ul></div><div><p><a data-tooltip-position="top" aria-label="evernote:///view/16130042/s156/484b3190-3053-ba8c-a046-62dcafe87d5e/22832c1a-34ab-449f-a394-cc556850e328/" rel="noopener" class="external-link" href="evernote:///view/16130042/s156/484b3190-3053-ba8c-a046-62dcafe87d5e/22832c1a-34ab-449f-a394-cc556850e328/" target="_blank">Multiple Myeloma: Relapsed</a></p></div><div class="mod-footer"></div></div></div></div></div></div></div></div><div class="sidebar-right sidebar"><div class="sidebar-gutter"><div class="clickable-icon sidebar-collapse-icon"><svg xmlns="http://www.w3.org/2000/svg" width="100%" height="100%" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="3" stroke-linecap="round" stroke-linejoin="round" class="svg-icon"><path d="M21 3H3C1.89543 3 1 3.89543 1 5V19C1 20.1046 1.89543 21 3 21H21C22.1046 21 23 20.1046 23 19V5C23 3.89543 22.1046 3 21 3Z"></path><path d="M10 4V20"></path><path d="M4 7H7"></path><path d="M4 10H7"></path><path d="M4 13H7"></path></svg></div></div><div class="sidebar-container"><div class="sidebar-sizer"><div class="sidebar-content-positioner"><div class="sidebar-content"><div class="graph-view-wrapper"><div class="sidebar-section-header">Interactive Graph</div><div class="graph-view-placeholder"><div class="graph-view-container"><div class="graph-icon graph-expand" role="button" aria-label="Expand" data-tooltip-position="top"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon"><line x1="7" y1="17" x2="17" y2="7"></line><polyline points="7 7 17 7 17 17"></polyline></svg></div><canvas id="graph-canvas" width="512px" height="512px"></canvas></div></div></div><div class="tree-container outline-tree" data-depth="0"><div class="tree-header"><span class="sidebar-section-header">Table Of Contents</span><button class="clickable-icon collapse-tree-button"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"></svg></button></div><div class="tree-scroll-area"><div class="tree-item" data-depth="1"><div class="tree-item-contents"><a class="internal-link tree-item-link" href="#Active_Multiple_Myeloma"><span class="tree-item-title"><p>Active Multiple Myeloma</p></span></a></div><div class="tree-item-children"><div class="tree-item" data-depth="3"><div class="tree-item-contents"><a class="internal-link tree-item-link" href="#**Clinical_Features_and_Complications_(SLIM_CRAB_HANd)**"><span class="tree-item-title"><p><strong>Clinical Features and Complications (SLIM CRAB HANd)</strong></p></span></a></div><div class="tree-item-children"></div></div><div class="tree-item" data-depth="3"><div class="tree-item-contents"><a class="internal-link tree-item-link" href="#**Amyloidosis**"><span class="tree-item-title"><p><strong>Amyloidosis</strong></p></span></a></div><div class="tree-item-children"></div></div><div class="tree-item" data-depth="3"><div class="tree-item-contents"><a class="internal-link tree-item-link" href="#**Revised_Staging_System_for_Myeloma_(RISS)_**"><span class="tree-item-title"><p><strong>Revised Staging System for Myeloma (RISS)</strong></p></span></a></div><div class="tree-item-children"></div></div></div></div><div class="tree-item" data-depth="1"><div class="tree-item-contents"><a class="internal-link tree-item-link" href="#Management"><span class="tree-item-title"><p>Management</p></span></a></div><div class="tree-item-children"><div class="tree-item" data-depth="3"><div class="tree-item-contents"><a class="internal-link tree-item-link" href="#**Management:_Initial**"><span class="tree-item-title"><p><strong>Management: Initial</strong></p></span></a></div><div class="tree-item-children"></div></div><div class="tree-item" data-depth="2"><div class="tree-item-contents"><a class="internal-link tree-item-link" href="#**General_Principles**"><span class="tree-item-title"><p><strong>General Principles</strong></p></span></a></div><div class="tree-item-children"></div></div></div></div></div></div></div></div></div></div></div></div></body></html>